AbbVie Inc. (NYSE:ABBV) [Trend Analysis] knocking active thrust in leading trading session, shares a decrease of -0.48% to 61.79 with around 1.08 Million shares have changed hands in this session. AbbVie (ABBV) reported that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for a shorter, eight-week treatment of VIEKIRAX + EXVIERA as an option for previously untreated adult patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) and minimal to moderate fibrosis*.VIEKIRAX + EXVIERA is currently authorized in the European Union for use as a 12-week treatment for GT1b chronic HCV-infected patients without cirrhosis or with compensated cirrhosis.
“AbbVie continuously strives to expand the utility of our HCV treatments, including investigating a shorter path to virologic cure for people living with HCV,” said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. “With this positive CHMP opinion, we will bring an eight-week treatment option for the many HCV patients with GT1b.” The stock is going forward its fifty-two week low with 18.28% and lagging behind from its 52-week high price with -7.53%.
Similar, the positive performance for the quarter recorded as 6.43% and for the year was 14.70%, while the YTD performance remained at 0.15%. ABBV has Average True Range for 14 days of 0.86.
VimpelCom Ltd. (NASDAQ:VIP) [Trend Analysis] retains strong position in active trade, as shares scoring -1.86% to $4.22 in active trade session, while looking at the shares volume, around 5.46 Million shares have changed hands in this session. VimpelCom Ltd. (VIP) declared that its fourth-quarter loss from continued operations widened to $273 million from a loss of $154 million, previous year. Operating profit reduced to $91 million from $166 million. Underlying EBITDA organically surged 1.2%. Profit to owners of the parent was $1.64 billion compared to $57 million, a year ago.
The company noted that its fourth-quarter profit to shareholders was positively impacted by the completion of the Italy joint venture transaction, partially offset by impairments, transformation costs and litigation provision.
Fourth-quarter total operating revenues were $2.35 billion compared to $2.30 billion, prior year. Group service revenue surged 3% primarily due to the Warid consolidation from third-quarter 2016. Total mobile consumers surged by approximately 10.6 million to 206.9 million at the end of fourth quarter 2016, mainly driven by the consolidation of Warid’s consumers in Pakistan from July 2016.
The VimpelCom Supervisory Board has authorized a new dividend policy and for the financial year ending 31 December 2016, VimpelCom intends to pay a dividend in the aggregate amount of 23 cents per share comprised of 3.5 cents per share paid as an interim dividend in December 2016 and 19.5 cents per share as a final dividend.
The record date for the company’s shareholders entitled to receive the final dividend payment has been set for 30 March 2017. It is expected that the final dividend will be paid in April 2017. The firm has institutional ownership of 10.10%, while insider ownership included 39.60%. VIP attains analyst recommendation of 1.90 with week’s performance of 0.00%. Investors looking further ahead will note that the Price to next year’s EPS is -16.88%.